Aims and background: Patients included in clinical trials are "selected", and they usually differ from those commonly treated. Methods: From 1999 to 2004, in the Medical Oncology Department of Padua (Italy), 70 metastatic colorectal cancers were treated with FOLFOX4. Results: Our results, compared with those of the registration trial (response rate, duration of response and progression-free survival) appeared lower; overall survival was improved. Conclusions: The number of therapeutic regimens more than their type influenced the results.
|Number of pages||4|
|Publication status||Published - May 2006|
- Colorectal cancer
ASJC Scopus subject areas
- Cancer Research